The stock of Tenaya Therapeutics Inc (TNYA) has seen a -8.25% decrease in the past week, with a -29.64% drop in the past month, and a -38.83% decrease in the past quarter. The volatility ratio for the week is 7.88%, and the volatility levels for the past 30 days are at 8.22% for TNYA. The simple moving average for the past 20 days is -15.70% for TNYA’s stock, with a -53.45% simple moving average for the past 200 days.
Is It Worth Investing in Tenaya Therapeutics Inc (NASDAQ: TNYA) Right Now?
TNYA has 36-month beta value of 2.35. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TNYA is 65.30M, and currently, short sellers hold a 8.00% ratio of that float. The average trading volume of TNYA on October 03, 2024 was 367.22K shares.
TNYA) stock’s latest price update
The stock price of Tenaya Therapeutics Inc (NASDAQ: TNYA) has plunged by -4.81 when compared to previous closing price of 1.87, but the company has seen a -8.25% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-03 that SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s chief Executive Officer, will participate in several upcoming investment conferences. Details are as follows:
Analysts’ Opinion of TNYA
Leerink Partners, on the other hand, stated in their research note that they expect to see TNYA reach a price target of $7. The rating they have provided for TNYA stocks is “Outperform” according to the report published on November 30th, 2023.
H.C. Wainwright gave a rating of “Buy” to TNYA, setting the target price at $25 in the report published on June 15th of the previous year.
TNYA Trading at -33.03% from the 50-Day Moving Average
After a stumble in the market that brought TNYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.61% of loss for the given period.
Volatility was left at 8.22%, however, over the last 30 days, the volatility rate increased by 7.88%, as shares sank -27.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.66% lower at present.
During the last 5 trading sessions, TNYA fell by -8.25%, which changed the moving average for the period of 200-days by -15.24% in comparison to the 20-day moving average, which settled at $2.0785. In addition, Tenaya Therapeutics Inc saw -45.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNYA starting from Saito Chihiro, who sale 2,363 shares at the price of $2.89 back on Aug 16 ’24. After this action, Saito Chihiro now owns 63,241 shares of Tenaya Therapeutics Inc, valued at $6,840 using the latest closing price.
Tingley Whittemore, the Chief Medical Officer of Tenaya Therapeutics Inc, sale 7,428 shares at $2.89 during a trade that took place back on Aug 16 ’24, which means that Tingley Whittemore is holding 107,106 shares at $21,500 based on the most recent closing price.
Stock Fundamentals for TNYA
Current profitability levels for the company are sitting at:
- -7.19 for the present operating margin
- 0.42 for the gross margin
The net margin for Tenaya Therapeutics Inc stands at -6.84. The total capital return value is set at -0.87. Equity return is now at value -74.54, with -62.89 for asset returns.
Based on Tenaya Therapeutics Inc (TNYA), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -6.28.
Currently, EBITDA for the company is -122.51 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 5.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.28.
Conclusion
To put it simply, Tenaya Therapeutics Inc (TNYA) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
